Approved for use frough 07/31/2008 CMS DEST-0337.

U.S. Patient and Trademark Office, U.S. Department of Processing Structure of Processing Structure

U.S. PATENTS

	Filing Date	2003-	
	First Named Inventor Henry		DaCo
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		2629
(NOTION SUDMISSION UNGER 57 OF K 1.33)	Examiner Name	Regin	a Liang

Attorney Docket Number		IMM174
Examiner Name Regir		ia Liang
Art Unit		2629
First Named Inventor	Henry	/ DaCosta
Filing Date		2003-11-26
Application Number		10723778

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	Name of Pat of cited Docu	entee or Applicant iment	Releva	Columns, ant Passa s Appear	ges or		nt
	1	5488204	A	1996-01	1-30	Carver A. Mea	ad					
	2	5889511	A	1999-03	1-30	Eng Yue Ong						
	3	7046235		2006-05	i-16	Takehiro Kato	h					
If you wisi	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add			_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	1		_
Examiner Initial*	Cite No	Publication Number	U.S.P Kind Code <sup>1</sup>	Publica			entee or Applicant	Releva	Columns ant Passa s Appear	Lines ges or		ınt
Examiner Initial*		Publication Number	Kind	Publica		Name of Pat	entee or Applicant	Releva	Columns	Lines ges or		ant
Initial*	No 1	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pat of cited Docu	entee or Applicant iment	Releva	,Columns ant Passa s Appear	Lines ges or		ant
Initial*	No 1		Kind Code <sup>1</sup>	Publica Date	ntion	Name of Pat of cited Docu	entee or Applicant iment	Releva	,Columns ant Passa s Appear	,Lines ges or		ant
Initial*	No 1		Kind Code <sup>1</sup>	Publica Date	ntion	Name of Pat of cited Docu n information   FENT DOCUM	entee or Applicant iment	Releve Figure	,Columns ant Passa s Appear	Jumns, levant	Releva	nnt Ts

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examin

pplication Number		10723778
iling Date		2003-11-26
irst Named Inventor	Henry	DaCosta
rt Unit		2629
xaminer Name Regir		a Liang
Marrier Davidsk Morale	nr	BB474

If you wish	to a	dd add	ditional Foreign Patent Document citation information please click the Add button	Add	
			NON-PATENT LITERATURE DOCUMENTS	Remove	
Examiner Cite Initials* On No Initials* Initials*					T5
	1				
If you wish	n to a	dd add	fitional non-patent literature document citation information please click the Add bu	utton Add	_
			EXAMINER SIGNATURE		
Examiner	Signa	ture	Date Considered		
			reference considered, whether or not citation is in conformance with MPEP 809, rmance and not considered. Include copy of this form with next communication to		

1 See Kind Codes of USPTO Patent Documents at www.ISPTO.QQU or MPEP 901.04. 2 Enter office that issued the document, by the hor-deter code (WIPO Standard 513.) 3 ero Justinese petant counters, the included not the year of the insper or may preced the serial runber of the petant of business of the Emperor want precede the serial runber of the petant of business of the Emperor want precede the serial runber of the petant of business of the Emperor want precede the serial runber of the petant of business of the Emperor want preceded the serial runber of the Petant Order of the Emperor want of the Emper

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10723778
Filing Date		2003-11-26
First Named Inventor Henry		DaCosta
Art Unit		2629
Examiner Name	Regin	a Liang
Attorney Docket Numb	ec	IMM174

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	to make the	appropriat	te selection(s):
---------------	----------	---------	-------------	------------	------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ...

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Carl E. Sanders/	Date (YYYY-MM-DD)	2007-04-03			
Name/Print	Carl E. Sanders	Registration Number	57,203			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol field not by the USPTO to process) and application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.